Want to see SVRA full AI Analyst Report?
Top Page
Savara
(NASDAQ:SVRA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$4.50
▼(-19.79% Downside)
Action:Reiterated
Date:08/18/26
The score is primarily weighed down by weak financial performance (no revenue, widening losses, and heavy cash burn despite a low-debt balance sheet) and bearish technical indicators (price below key moving averages with negative MACD). Valuation provides limited support due to negative earnings, while corporate actions expand financing flexibility but also raise dilution risk.
Positive Factors
Low leverage
Low leverage reduces fixed financial obligations and gives Savara more flexibility than a heavily indebted biotech. This structure can help preserve strategic options while the company advances development programs and seeks funding for continued operations.
Negative Factors
No commercial revenue
The absence of revenue means Savara has not yet demonstrated commercial product demand or an operating sales engine. Until a product reaches the market, the company cannot fund development through customers and remains dependent on capital markets or other financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Low leverage reduces fixed financial obligations and gives Savara more flexibility than a heavily indebted biotech. This structure can help preserve strategic options while the company advances development programs and seeks funding for continued operations.
Read all positive factors
Savara (SVRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.03B
Dividend YieldN/A
Average Volume (3M)2.49M
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue GrowthN/A
EPS Growth-12.40%
CountryUS
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.58
Shares Outstanding205,460,020
10 Day Avg. Volume2,729,188
30 Day Avg. Volume2,491,440
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-68.57
Enterprise Value/Ebitda-10.21
Forecast
1Y Price Target
$11.33Price Target Upside102.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$2.30M
Savara Business Overview & Revenue Model
Company Description
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimula...
Savara Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -20.70M | -245.00K | -78.03M | -44.26M | -27.88M | -28.99M |
| EBITDA | -139.03M | -118.75M | -102.27M | -59.13M | -37.88M | -40.27M |
| Net Income | -139.31M | -118.84M | -95.88M | -54.70M | -38.15M | -43.01M |
Balance Sheet | ||||||
| Total Assets | 192.14M | 253.44M | 212.88M | 177.56M | 139.78M | 176.60M |
| Cash, Cash Equivalents and Short-Term Investments | 173.03M | 235.70M | 196.33M | 162.32M | 125.88M | 161.17M |
| Total Debt | 30.11M | 29.91M | 26.73M | 26.49M | 26.14M | 25.79M |
| Total Liabilities | 48.48M | 50.30M | 41.43M | 37.19M | 32.00M | 32.10M |
| Stockholders Equity | 143.66M | 203.13M | 171.45M | 140.37M | 107.78M | 144.50M |
Cash Flow | ||||||
| Free Cash Flow | -110.66M | -101.06M | -89.11M | -51.36M | -34.56M | -40.14M |
| Operating Cash Flow | -110.38M | -101.04M | -89.09M | -51.06M | -34.55M | -40.08M |
| Investing Cash Flow | -721.00K | -18.44M | -39.94M | -57.12M | 52.65M | -69.46M |
| Financing Cash Flow | 135.53M | 137.81M | 117.58M | 82.78M | 87.00K | 120.81M |
Savara Technical Analysis
Neutral
5.61
Price Trends
5.10
Negative
5.37
Negative
5.40
Negative
Market Momentum
-0.11
Negative
54.45
Neutral
75.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SVRA, the sentiment is Neutral. The current price of 5.61 is above the 20-day moving average (MA) of 4.73, above the 50-day MA of 5.10, and above the 200-day MA of 5.40, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 54.45 is Neutral, neither overbought nor oversold. The STOCH value of 75.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SVRA.
Savara Risk Analysis
Savara disclosed 37 risk factors in its most recent earnings report. Savara reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Savara Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $1.53B | 4.34 | 30.03% | 7.39% | 18.17% | 693.83% | |
58 Neutral | $1.29B | 9.36 | -109.40% | ― | ― | ― | |
54 Neutral | $751.78M | -35.65 | -15.77% | 642.31% | 16.83% | -494.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $714.31M | -4.75 | -41.33% | ― | 278712.12% | 26.59% | |
45 Neutral | $1.03B | -8.66 | -90.28% | ― | ― | -12.40% |
* Healthcare Sector Average
SVRA
Savara
5.02
0.68
15.67%
OMER
Omeros
17.88
10.20
132.81%
GYRE
Gyre Therapeutics
7.09
-0.45
-5.97%
INVA
Innoviva
21.12
3.55
20.20%
FDMT
4D Molecular Therapeutics
12.93
1.52
13.32%
AVLN
Avalyn Pharma Inc
25.74
-3.75
-12.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.